ROIVANT SCIENCES LTD. Income Taxes Receivable, Current
ROIVANT SCIENCES LTD. (ROIV) had Income Taxes Receivable, Current of $44.91 million as of 2024-12-31, per its 10-Q filed 2025-02-10.
Financial Statements › Notes
us-gaap:IncomeTaxesReceivable · last filed 2025-02-10
- 2024-12-31: Income Taxes Receivable, Current $44.91M.
- 2024-09-30: Income Taxes Receivable, Current $6.89M.
- 2024-06-30: Income Taxes Receivable, Current $2.40M.
- 2024-03-31: Income Taxes Receivable, Current $1.32M; Income Taxes Receivable, Current as first filed $1.83M.
| Period end | Income Taxes Receivable, Current | Income Taxes Receivable, Current as first filed |
|---|---|---|
| 2024-12-31 | $44.91M 10-Q · filed 2025-02-10 | |
| 2024-09-30 | $6.89M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $2.40M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $1.32M 10-Q · filed 2025-02-10 | $1.83M 10-K · filed 2024-05-30 |
| 2023-12-31 | $3.21M 10-Q · filed 2024-02-13 | |
| 2023-09-30 | $2.51M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $2.85M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $2.36M 10-K · filed 2024-05-30 | |
| 2022-12-31 | $1.49M 10-Q · filed 2023-02-13 | |
| 2022-09-30 | $2.33M 10-Q · filed 2022-11-14 | |
| 2022-03-31 | $2.85M 10-K · filed 2023-06-28 | |
| 2021-12-31 | $2.63M 10-Q · filed 2022-02-14 | |
| 2021-09-30 | $2.50M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $1.99M 10-Q · filed 2021-09-21 | |
| 2021-03-31 | $1.80M 10-Q · filed 2022-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |